TRELSTAR - Reimbursement & Support Programs

1. TRELSTAR Support Line

For your convenience the TRELSTAR Support Line is available. For comprehensive support services, including information on ordering TRELSTAR, reimbursement, Indigent Patient Program, drug safety and adverse event reporting and medical and general nonmedical information.

Call 866-755-3315

OPTION 2 - TRELSTAR Reimbursement Services
Reimbursement counselors are available from 9:00 AM to 8:00 PM EST to help you with the following services:

Insurance coverage verification

Contacting insurers to determine each patient’s insurance coverage, co-payment obligations, and availability of benefits.
Providing information and general assistance regarding insurers’ pre-certification and prior-authorization procedures.

Coding and coverage

Confirming proper coding to use on claim forms.
Providing guidance and updated information regarding payer policies for physicians, reimbursement managers, and other office staff.

Claim review and denial assistance

Reviewing denied claims for accuracy and completeness.
Obtaining appropriate reimbursement by assisting in the denial and appeals process.
Preparing a letter of medical necessity.
Communicating with your office to ensure that appealed claims are reimbursed appropriately.

Indigent Patient Program

Screening patients for eligibility and enrolling indigent patients who need assistance obtaining TRELSTAR.
Identifying alternate funding sources for patients who are uninsured or underinsured.

OPTION 3 - Medical Affairs

Side effect/adverse events reporting

Allows you to report side effects or adverse events related to TRELSTAR or other Watson products.

Medical information

Professionals from Watson’s Medical Communications Department will answer your medical questions about TRELSTAR or other Watson products.

Quality control and assurance

Allows you to report a product quality-related complaint regarding TRELSTAR or other Watson products.

OPTION 4 - TRELSTAR Nonmedical General Information
Obtain answers to your general questions about TRELSTAR

2. Reimbursement Guide
Watson Pharma is committed to providing your office with ample reimbursement support services and is pleased to provide you with the 2005 TRELSTAR Reimbursement Guide. The purpose of this guide is to assist physicians and medical billing staff with billing and reimbursement for TRELSTAR and to provide guidance in filing a claim for TRELSTAR therapy.

This guide is provided to you for informational purposes only. For current or additional information regarding billing and reimbursement, please call the TRELSTAR Support Line at 866-755-3315 .

Click here to download a PDF file of the guide

3. Patient Assistance Program
To help uninsured patients who require medical intervention with TRELSTAR, Watson has designed the TRELSTAR Indigent Patient Program. Through this program, TRELSTAR is provided free of charge to low-income patients who are uninsured and meet financial eligibility requirements. If you have a patient who may be eligible for this program:

Call the TRELSTAR Support Line and explain your patient’s situation to the Support Line counselor, who may be able to suggest other sources of coverage
If there is no other source of payment available, the Support Line consultant will send you a qualification form that requests insurance status and income information. Patient eligibility must be demonstrated. The form must be completed, signed, and returned to the TRELSTAR Support Line representative with a prescription for the patient’s course of TRELSTAR therapy. Additionally, an authorization to disclose information about the patient in the Indigent Patient Program will also need to be completed
A Support Line consultant will review your patient’s eligibility status. You will be notified by telephone or fax of the patient’s eligibility status
As soon as it has been determined that a patient is qualified to receive TRELSTAR free of charge, Watson will provide the medication as prescribed by the physician. The product will be sent to the physician’s office to be administered to the patient
Watson reserves the right to modify or discontinue the TRELSTAR Indigent Patient Program at any time

Request Additional Information

Indications and Usage
TRELSTAR^® Depot and TRELSTAR^® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

Safety Information

The most commonly reported adverse events associated with the use of TRELSTAR^® Depot/TRELSTAR^® LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.